KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Liabilities (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Total Liabilities data on record, last reported at $7.0 billion in Q4 2025.

  • For Q4 2025, Total Liabilities rose 13.94% year-over-year to $7.0 billion; the TTM value through Dec 2025 reached $7.0 billion, up 13.94%, while the annual FY2025 figure was $7.0 billion, 13.94% up from the prior year.
  • Total Liabilities reached $7.0 billion in Q4 2025 per VRTX's latest filing, down from $7.5 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $7.5 billion in Q3 2025 and bottomed at -$15.6 billion in Q3 2024.
  • Average Total Liabilities over 5 years is $3.8 billion, with a median of $4.7 billion recorded in 2023.
  • Peak YoY movement for Total Liabilities: crashed 399.82% in 2024, then skyrocketed 148.26% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $3.3 billion in 2021, then rose by 27.18% to $4.2 billion in 2022, then grew by 21.51% to $5.1 billion in 2023, then increased by 18.91% to $6.1 billion in 2024, then increased by 13.94% to $7.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $7.0 billion in Q4 2025, $7.5 billion in Q3 2025, and $6.9 billion in Q2 2025.